.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Physicians widely prescribe Gliclazide as a cornerstone sulfonylurea for the management of type 2 diabetes mellitus. However, its poor aqueous solubility often limits its therapeutic efficacy and bioavailability. Recent pharmaceutical advancements in gliclazide dissolution enhancement now utilize room-temperature atomic layer deposition (ALD) to address these formulation challenges. By applying ultra-thin SiO2 films directly to drug particles, researchers have successfully transformed the drug's physical properties for better clinical performance.
The core problem with gliclazide lies in its strongly hydrophobic nature. This characteristic prevents the drug particles from dispersing effectively in aqueous media. Consequently, patients may experience inconsistent absorption and varying drug levels in the bloodstream. However, the application of ultra-thin silica coatings through ALD changes the particle surface to a highly hydrophilic state. This critical modification promotes a highly dispersed state in the gastrointestinal environment. Furthermore, the SiO2 coating significantly accelerates the dissolution process. Notably, engineers can now tailor the drug's release kinetics by simply adjusting the coating thickness. Therefore, this technology provides a precise, multipurpose design for controlled drug delivery.
Moreover, this surface engineering approach aligns perfectly with existing pharmaceutical manufacturing standards. Since many modern medications face similar solubility issues, ALD presents a versatile solution for the industry. It not only overcomes traditional solubility limitations but also optimizes the release profiles of other poorly soluble chemical entities. Thus, healthcare providers can eventually expect more predictable and optimized therapeutic outcomes with these advanced gliclazide formulations. This innovation represents a promising pathway for improving the bioavailability of essential antidiabetic therapies.
Atomic layer deposition applies a nanometer-scale SiO2 layer that converts the hydrophobic drug surface into a hydrophilic one. This change ensures better dispersion and a faster dissolution rate in aqueous environments like the digestive tract.
Tunable dissolution allows researchers to control exactly how fast the medication enters the circulation. By varying the SiO2 coating thickness, manufacturers can create tailored drug release kinetics to suit different therapeutic needs.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
1. Cao VP et al. Tunable dissolution of poorly soluble gliclazide by surface coating via room-temperature atomic layer deposition. J Chem Phys. 2026 Jun 14. doi: undefined. PMID: 42283359.
2. Das S et al. The Role of Gliclazide as a Preferred Modern Sulfonylurea. Curr Trends Intern Med. 2025 May 23. doi: 10.29011/2638-003X.100243.
3. Ibrahim BA et al. Enhancing gliclazide solubility using solid dispersions with carboxymethyl chitosan and polyvinylpyrrolidone K30 as polymeric carriers. Drug Dev Ind Pharm. 2025 May 28. doi: 10.1080/03639045.2025.2359401.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study highlights the use of room-temperature atomic layer deposition (ALD) to apply ultra-thin SiO2 films to gliclazide. This process enhances the drug's wettability and provides a tunable dissolution profile, promising improved bioavailability for this widely used antidiabetic medication.
2 months ago
A new case study illuminates how functional connectivity changes drive recovery from pure alexia following posterior cerebral artery infarction. Functional reorganization supports reading recovery despite permanent structural tract disconnection, highlighting key implications for stroke rehabilitation.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
